<DOC>
	<DOCNO>NCT00002826</DOCNO>
	<brief_summary>RATIONALE : Some tumor become resistant chemotherapy drug . Combining PSC 833 chemotherapy drug may reduce resistance drug , allow tumor cell kill . PURPOSE : Phase II trial study effectiveness PSC 883 paclitaxel treat woman recurrent metastatic breast cancer .</brief_summary>
	<brief_title>Drug Resistance Inhibition Treating Women With Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate antitumor activity , measure frequency objective response time progression , multidrug resistance modulator PSC 833 combination paclitaxel woman recurrent metastatic breast cancer . II . Describe toxicity regimen . OUTLINE : All patient receive PSC 833 mouth every 6 hour total 12 dos . Paclitaxel infuse 3 hour , 5th dose PSC 833 . Treatment repeat every 3 week stable respond patient . PSC 833 must mix grapefruit juice . Growth factor may use discretion investigator . Patients follow every 3 month first two year , every 6 month year 2-5 , annually thereafter . PROJECTED ACCRUAL : It anticipate approximately 36 patient enter 24 month least 6 response first 17 patient .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma breast recurrent metastatic No CNS metastases Bidimensionally measurable disease require Patients bone sit eligible Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Women Menopausal status : Not specify Performance status : ECOG 02 Hematopoietic : Platelet count least 100,000/mm3 Absolute granulocyte count least 1,500/mm3 Hepatic : Bilirubin great 1.5 mg/dL AST le 2.5 time upper limit normal Renal : Creatinine great twice upper limit normal Other : No allergy cyclosporine drug formulate Cremophor ( e.g. , anesthetic muscle relaxant ) No active unresolved infection More 7 day since parenteral antibiotic No second malignancy within 5 year except : In situ cervical cancer Nonmelanomatous skin cancer No pregnant nursing woman Adequate contraception require fertile woman PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Prior anthracyclines medical contraindication anthracycline therapy require No prior paclitaxel taxotere No 1 prior regimen metastatic recurrent disease Adjuvant chemotherapy within 6 month diagnosis metastatic disease consider therapy advance disease At least 3 week since chemotherapy Endocrine therapy : At least 3 week since hormonal therapy metastasis Radiotherapy : Not specify Surgery : Not specify Other : No concurrent treatment follow agent proven affect blood level cyclosporine : Diltiazem Nicardipine Verapamil Fluconazole Itraconazole Ketoconazole Clarithromycin Erythromycin Methylprednisolone Prednisolone Allopurinol Bromocriptine Danazol Metoclopramide Nafcillin Rifampin Carbamazepine Phenobarbital Phenytoin Octreotide Ticlopidine</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>